IRCCS - ASSOCIAZIONE LA NOSTRA FAMIGLIA 'ISTITUTO SCIENTIFICO EUGENIO MEDEA'

Their core work

Istituto Scientifico Eugenio Medea is an Italian clinical research centre (IRCCS) specializing in child neurology, developmental disabilities, and neurorehabilitation. Their core work centres on understanding neurodevelopmental conditions — particularly autism and intellectual disability — through clinical trials and biomarker research. They also investigate the intersection of mental health with emerging workplace technologies, notably collaborative robots (cobots) in industrial settings. As part of the La Nostra Famiglia association, they combine clinical care with scientific research on children and young people with neurological and developmental conditions.

What they specialise in

How they've shifted over time

Their early H2020 work (2018) focused on cognitive and linguistic development, particularly multilingualism in migrant and refugee populations through MultiMind. By 2020, their focus shifted decisively toward applied mental health — coordinating MindBot on worker wellbeing alongside cobots, while continuing autism-related clinical research via AIMS-2-TRIALS. The trajectory shows a move from fundamental cognitive science toward more applied, technology-adjacent mental health research with direct industrial relevance.

MEDEA is moving toward the intersection of mental health and workplace technology, making them a relevant partner for Industry 4.0 projects that need human factors and psychological wellbeing expertise.

How they like to work

MEDEA operates as both a leader and a contributor — they coordinated MindBot (their largest project by far) while participating in two other consortia. With 99 unique partners across 18 countries from just 3 projects, they have worked within large, international consortia rather than small focused teams. This suggests comfort operating in complex multi-partner environments and an ability to bring clinical and psychological research expertise into diverse interdisciplinary groups.

Despite only three projects, MEDEA has built a broad network of 99 partners across 18 countries — largely because AIMS-2-TRIALS is a major multi-site consortium. Their reach is firmly pan-European with no narrow geographic concentration.

What sets them apart

MEDEA's distinctive strength is combining clinical neuroscience credibility (as an IRCCS — Italy's designation for top-tier clinical research institutes) with applied mental health research in non-medical domains like manufacturing. Few organizations can bridge child neurodevelopment, autism clinical trials, AND occupational mental health for Industry 4.0. For consortium builders, they offer a rare profile: rigorous clinical methodology applied to human-technology interaction questions that most health institutes would not touch.

Highlights from their portfolio

• MindBot
  Their only coordinated project and largest funding (EUR 836K), tackling the unusual intersection of mental health and collaborative robots in manufacturing — a topic bridging health and Industry 4.0.
• AIMS-2-TRIALS
  A flagship European autism research initiative running until 2026, connecting MEDEA to one of the largest neurodevelopmental research consortia in H2020 despite their minimal direct funding (EUR 3K suggests a linked third-party or in-kind role).